Chinese Journal of Tissue Engineering Research ›› 2025, Vol. 29 ›› Issue (25): 5289-5295.doi: 10.12307/2025.520

Previous Articles     Next Articles

Expression of Rab27A in ovarian tissue of polycystic ovary syndrome model mice treated with human umbilical cord mesenchymal stem cells

Tao Chenyue1, Chen Shuai2, Wang Liping3, Meng Defang4, Zhou Dongjie5, Zhou Luojing6   

  1. 1School of Public Health, Yangzhou University, Yangzhou 225001, Jiangsu Province, China; 2College of Veterinary Medicine of Yangzhou University, Institute of Comparative Medicine of Yangzhou University, Yangzhou 225009, Jiangsu Province, China; 3Department of Biobank, 4Department of Rheumatology and Immunology, 5Department of Maternity, 6Department of Science and Technology, Northern Jiangsu People’s Hospital Affiliated to Yangzhou University, Yangzhou 225001, Jiangsu Province, China
  • Received:2024-04-10 Accepted:2024-05-30 Online:2025-09-08 Published:2024-12-14
  • Contact: Wang Liping, PhD, Associate researcher, Department of Biobank, Northern Jiangsu People’s Hospital Affiliated to Yangzhou University, Yangzhou 225001, Jiangsu Province, China
  • About author:Tao Chenyue, Master candidate, School of Public Health, Yangzhou University, Yangzhou 225001, Jiangsu Province, China
  • Supported by:
    National Natural Science Foundation of China (Youth Project), No. 82001512 (to WLP); Jiangsu Provincial Science and Technology Plan (General Project), No. BK20211118 (to WLP); Jiangsu Provincial Health Commission Medical Research General Project, No. M2021044 (to WLP) 

Abstract: BACKGROUND: Polycystic ovary syndrome is a common reproductive endocrine disease leading to infertility in women of reproductive age. Currently, there is no effective treatment. Human umbilical cord mesenchymal stem cells may help to repair ovarian function, but few studies have reported their role in the treatment of polycystic ovary syndrome.
OBJECTIVE: To explore the effect and mechanism of human umbilical cord mesenchymal stem cells in the treatment of polycystic ovary syndrome. 
METHODS: 3-week-old female ICR mice were divided into three groups (n=15). Normal control group was not treated. Model group was given letrozole for 21 days to induce polycystic ovary syndrome. Treatment group was given letrozole via intragastric administration for 21 consecutive days, and human umbilical cord mesenchymal stem cell suspension was injected through the tail vein. The body weight of mice was monitored before treatment, 7 and 14 days after treatment. The estrous cycle of mice was detected by continuous vaginal smears for 10 consecutive days after treatment. Fourteen days after treatment, peripheral blood sex hormone levels of mice were detected by ELISA. Hematoxylin-eosin staining was used to observe ovarian morphological changes. Immunofluorescence and immunohistochemistry were used to detect the expression of Rab27A protein in ovarian tissues. 
RESULTS AND CONCLUSION: (1) Compared with the normal control group, the estrous cycle of mice in the model group was disturbed; body weight was significantly increased; follicle stimulating hormone was decreased; luteinizing hormone and testesterone were both increased; more follicles were found in the ovaries, and the relative expression level of Rab27A protein was decreased. (2) Compared with the model group, the treatment group had diminished body weight, increased follicle stimulating hormone, decreased luteinizing hormone and testesterone, decreased follicles with polycystic dilatation, and increased Rab27A protein relative expression level. (3) These findings suggest that human umbilical cord mesenchymal stem cells improve serum sex hormone levels and ovarian function in polycystic ovary syndrome mice by upregulating the expression of Rab27A.

Key words: human umbilical cord mesenchymal stem cell, polycystic ovary syndrome, estrous cycle, ovarian function, sex hormone, Rab27A

CLC Number: